provider image
Welcome! You’re in GoodRx for healthcare professionals. Now, you’ll enjoy a streamlined experience created specifically for healthcare professionals.
Skip to main content
Gohibic Coupon - Gohibic 20ml of 200mg/20ml vial

Gohibic

vilobelimab
Used for COVID-19
Used for COVID-19

Gohibic (vilobelimab) is a monoclonal antibody that's used to treat illness due to COVID-19 infection in adults who are in the hospital. It must be started within 48 hours of intubation. This medication is given as an injection into the veins by a trained healthcare provider. Gohibic (vilobelimab) has been authorized by the FDA under emergency use authorization (EUA).

Reviewed by:
reviewer
Kristianne Hannemann, PharmD
reviewer
Cydnee Ng, PharmD
Last reviewed on August 22, 2023
BasicsFAQsAlternativesLatest newsImagesReferencesPricesMedicare
basics-icon

What is Gohibic (vilobelimab)?

What is Gohibic (vilobelimab) used for?

How Gohibic (vilobelimab) works

Gohibic (vilobelimab) is a monoclonal antibody that works as a complement C5a inhibitor. It blocks certain proteins that are part of your body's immune system called C5a. Gohibic (vilobelimab) helps block the C5a proteins from sending out signals that cause inflammation and damage to different organs in the body when you have a COVID-19 infection.

Drug Facts

Common BrandsGohibic
Drug ClassComplement C5a inhibitor
Controlled Substance ClassificationNot a controlled medication
Generic StatusNo lower-cost generic available
AvailabilityNot FDA-approved yet
faqs

Frequently asked questions about Gohibic (vilobelimab)

Who is eligible to receive Gohibic (vilobelimab)?
Gohibic (vilobelimab) is only authorized for use in adults who are in the hospital and have a COVID-19 infection. Additionally, it can only be given within 48 hours of receiving invasive mechanical ventilation, such as a breathing tube, or extracorporeal membrane oxygenation (ECMO). Gohibic (vilobelimab) isn't authorized for use in children.
How is Gohibic (vilobelimab) given?
Gohibic (vilobelimab) is given as an injection into the veins (intravenously or IV) by a trained healthcare provider. You'll typically receive 800 mg of Gohibic (vilobelimab) per day for a maximum of 6 doses following a specific treatment schedule. These doses are given on days 1, 2, 4, 8, 15, and 22 of Gohibic (vilobelimab) treatment. Each IV infusion typically takes 30 to 60 minutes.
How well does Gohibic (vilobelimab) work?
In clinical studies, there were fewer deaths overall in the group of people who were treated with Gohibic (vilobelimab) than in the group of people who took a placebo. Over a 28-day period, about 32% of hospitalized adults with COVID-19 who required invasive mechanical ventilation or ECMO and were treated with Gohibic (vilobelimab) died compared to about 42% of those treated with placebo. Researchers saw similar results when they looked at a 60-day period after treatment with Gohibic (vilobelimab). This suggests that Gohibic (vilobelimab) might lower the risk of death by day 28 and day 60 of treatment compared to not taking the medication.
What are common side effects of Gohibic (vilobelimab)?
Pneumonia, sepsis (extreme reaction to an infection), delirium (confused thinking and changes in alertness), and blood clot in the lungs were some of the most common side effects that people had during clinical studies of Gohibic (vilobelimab). Your healthcare team will monitor you closely for side effects from Gohibic (vilobelimab) while you're in the hospital and treat you appropriately when needed.
Are there risks to receiving Gohibic (vilobelimab)?
Yes. Since Gohibic (vilobelimab) affects your immune system, the medication might raise your risk for serious bacterial, fungal, and viral infections. Watch out for signs of infection, such as a fever, chills, diarrhea, pain while urinating, and cough. Let your provider know right away if you experience any new or worsening symptoms. Additionally, Gohibic (vilobelimab) can sometimes cause a severe allergic reaction. Get medical help as soon as possible if you experience trouble breathing, hives, or swelling in your face or throat.
GoodRxEducationalIcon

How to save using GoodRx

Compare Prices
1. Compare PricesSpecify your dosage and quantity to find out exactly how much you can save.
Select your free coupon
2. Select your free couponYou can use the displayed coupon, or compare prices at other pharmacies near you.
Show coupon to your pharmacist
3. Show coupon to your pharmacistPresent your printed or electronic coupon when you pick up your prescription.
Get free couponLearn more
alternatives

What are alternatives to Gohibic (vilobelimab)?

There are a number of medications that your doctor can prescribe in place of Gohibic (vilobelimab). Compare a few possible alternatives below.
Gohibic (vilobelimab)
Used for:
View Prices
Olumiant (baricitinib)
Used for:
View Prices
Actemra (tocilizumab)
Used for:
View Prices
images

Gohibic (vilobelimab) images

colorless - GOHIBIC 200mg / 20mL Solution for Infusion
This medicine is Colorless Vial.colorless - GOHIBIC 200mg / 20mL Solution for Infusion

Get savings updates for Gohibic (vilobelimab)

Receive price alerts, news, and other messages from GoodRx about Gohibic (vilobelimab) and other healthcare topics and relevant savings offers.

By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.

References

Best studies we found

American Thoracic Society. (2016). What is ECMO?

Delves, P. J. (2022). Innate immunity. Merck Manual Consumer Version.

Huang, J. (2023). Delirium. Merck Manual Consumer Version.

View All References (4)

InflaRx GmbH. (2023). Gohibic- vilobelimab injection [package insert]. DailyMed.

U.S. Food and Drug Administration. (2023). FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19.

Vlaar, A. P. J., et al. (2022). Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet: Respiratory Medicine.

Walter, J. M., et al. (2018). Invasive mechanical ventilation. Southern Medical Journal.

GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.
Was this page helpful?

Browse medications

View All

Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.